Molecure can proceed with clinical trials in the U.S.A – Phase II proof-of-concept study will be the first to treat patients suffering from pulmonary sarcoidosis with OATD-01 In the coming weeks Molecure will also seek the
Read moreInitiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). World's
Read more- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the phase II clinical trial (KITE study), patients will
Read moreMolecure strategy update for 2023-2025 based on the development of a diversified portfolio of innovative research projects with the potential for breakthrough therapies for incurable diseases Completed successful Secondary Public Offering (SPO) of gross proceeds of
Read moreMMP9 – PBS3/A8/36/2015 - Inhibitory MMP-9 jako nowy lek blokujący rozwój padaczki Na padaczkę w Polsce choruje około 400 tysięcy osób, a roczne jej koszty w UE wynoszą 14 mld EUR. Nowym podejściem do leczenia padaczki jest
Read moreMarta Dudek, MD, PhD, received her PhD degree in biochemistry from the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences, in collaboration with the University of Warsaw in 2012. She has worked with oncological patients
Read moreOncoArendi Therapeutics SA today signed an agreement with VIB, one of the world leading life science research institutes. The scope of this research collaboration focuses on the role of chitinase and chitinase-like-proteins (CLPs) in COVID-19 and
Read more
